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EFFECT OF COMPLIANCE ON HEALTH
AND ECONOMIC OUTCOMES: ROLE OF
CONJUGATED ESTROGEN ON DEPRESSION
AND CARDIOVASCULAR DISORDERS.
Heaton AHI, Flinner AI, Martin SLI, Emmett KP, Buatti Me2
'Pharmacy Gold, Eagan, MN, USA; 2Wyeth-Ayerst
Laboratories, Philadelphia, PA USA
OBJECTIVE: The study purpose was to identify the ef-
fect of compliance with conjugated estrogen on subse-
quent clinical event rates and their economic impact.
METHODS: Claims from a large Midwest health care
plan were screened to identify females receiving a new
prescription for conjugated estrogen from 7/1/93 to 6/30/
94 and continuing enrollment to 12/31/96. Compliance
was calculated by prescription fill quantity divided by en-
rollment days. Two subgroups (100% compliant versus
one prescription only) were analyzed. Endpoints were the
diagnosis of depression, myocardial infarction or conges-
tive heart failure, physician office visits, and total health
care expenditures.
RESULTS: 1112 patients (mean age 57.87) were 100%
compliant; mean follow-up, 42.1 months. 900 patients
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(mean age 57.62) received one prescription only; mean
follow-up, 41.8 months. Diagnostic rates between the
groups were not different for depression, but less (p >
.05) in the compliant group for cardiovascular disorders.
Office visit rates were less (p > .0001) in the compliant
group for depression and cardiovascular disorders. Total
health care expenditures were $220 per patient per
month (pppm) for the compliant group and $251 pppm
for the non-compliant group (p > .05). Pharmacy expen-
ditures were higher in the compliant group ($74.84 to
$53.62 pppm), but medical costs in the non-compliant
group exceeded that differential.
CONCLUSIONS: Compliance with conjugated estrogen
therapy reduced the diagnostic rate of selected cardiovas-
cular disorders and decreased office visit rates for selected
disorders. Total health care expenditure was less in the
compliant group. The relatively short time frame to these
results is especially attractive to health care plans.
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CONFOUNDING BY INDICATION IN CALCIUM
CHANNEL BLOCKER TREATMENT OF
HYPERTENSION OR ANGINA
Mallick RI, Leader SI, Roht L2
'Pracon, Reston, VA, USA; 2Hoechst Marion Roussel, Kansas
City, MO, USA
Observational studies of calcium channel blockers (CCBs)
prescribed for hypertension or angina may be subject to
indication bias if this class of drugs is selectively pre-
scribed to patients at higher risk due to comorbidities.
OBJECTIVE: To determine if prescribing of calcium chan-
nel blockers is associated with prior diagnoses of condi-
tions known to be risk factors for cardiovascular events.
METHODS: Using Pennsylvania Medicaid's paid claims
data, we identified all continuously enrolled recipients
aged 18 to 61 who filled at least one prescription for an
antihypertensive or antianginal medication in 1990,
1991, or 1992. An index date equal to the date of the
first dispensed prescription in that period was created. All
medical and prescription claims during the year prior to
the index date were examined for the existence and dates
of relevant diagnoses that preceded any prior classes of
pharmacotherapy. Chi-square tests of associations be-
tween each such diagnosis and each class of subsequent
pharmacotherapy were conducted.
RESULTS: Among 11,141 patients with prior monother-
apy, CCB treated patients (n = 1,703) had significantly
(p < 0.01) greater odds of a prior diagnosis of acute myo-
cardial infarction (AMI), angina, arteriosclerotic cardio-
vascular disease, COPD, diabetes, ischemic heart disease,
or hypertension than those treated with beta blockers
(n = 2,684), diuretics (n = 4,188) or any non-CCB
monotherapy (n = 9,438). Except for AMI, these results
were confirmed when we examined diagnoses made 7
days or less before the first prescription was dispensed in
the prior year.
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CONCLUSIONS: Because subjects in observational stud-
ies are not randomized, confounding by indication must
be explicitly measured by testing the association between
prior risk factors and the selection of initial pharmaco-
therapy class. CCBs are susceptible to indication bias.
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